Fidelis Capital Partners’s ResMed RMD Stock Holding History

Fidelis Capital Partners’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$245K	Sell	1,257 -42	-3%	-$8.71K	0.01%	483
2026 Q1	$292K	Buy	1,299 +29	+2%	+$7.23K	0.02%	408
2025 Q4	$306K	Sell	1,270 -4	-0.3%	-$1.02K	0.02%	390
2025 Q3	$349K	Buy	1,274 +96	+8%	+$26.2K	0.03%	365
2025 Q2	$330K	Buy	1,178 +115	+11%	+$27.4K	0.03%	329
2025 Q1	$251K	Sell	1,063 -47	-4%	-$11K	0.03%	360
2024 Q4	$267K	Buy	1,110 +11	+1%	+$2.65K	0.03%	357
2024 Q3	$261K	Buy	1,099 +12	+1%	+$2.68K	0.03%	339
2024 Q2	$229K	Buy	1,087 +6	+0.6%	+$1.22K	0.03%	330
2024 Q1	$214K	Buy	+1,081	New	+$198K	0.03%	346

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Fidelis Capital Partners's RMD Position: Q2 2026 in Review

Fidelis Capital Partners reduced its ResMed (RMD) stake by 3.2% in Q2 2026, selling an estimated $8.71K and leaving 1,257 shares worth $245K. The position accounts for 0.01% of the portfolio, ranked #483.

Fidelis Capital Partners first reported a position in RMD in Q1 2024 and has held it in 10 quarters since. The position peaked at $349K in Q3 2025. 891 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

Fidelis Capital Partners held 1,257 shares of ResMed worth $245K as of Q2 2026.
Fidelis Capital Partners sold 42 ResMed shares in Q2 2026, an estimated $8.71K.
ResMed made up 0.01% of Fidelis Capital Partners's portfolio in Q2 2026, its #483 holding.
Fidelis Capital Partners first reported a position in ResMed in Q1 2024 and has held it in 10 quarters since.
Fidelis Capital Partners's ResMed position peaked at $349K in Q3 2025.
891 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Fidelis Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.